GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huadong Medicine Co Ltd (SZSE:000963) » Definitions » Cash-to-Debt

Huadong Medicine Co (SZSE:000963) Cash-to-Debt : 2.65 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Huadong Medicine Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Huadong Medicine Co's cash to debt ratio for the quarter that ended in Dec. 2023 was 2.65.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Huadong Medicine Co could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Huadong Medicine Co's Cash-to-Debt or its related term are showing as below:

SZSE:000963' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.39   Med: 1.76   Max: 2.65
Current: 2.65

During the past 13 years, Huadong Medicine Co's highest Cash to Debt Ratio was 2.65. The lowest was 0.39. And the median was 1.76.

SZSE:000963's Cash-to-Debt is ranked better than
64.6% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.945 vs SZSE:000963: 2.65

Huadong Medicine Co Cash-to-Debt Historical Data

The historical data trend for Huadong Medicine Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Huadong Medicine Co Cash-to-Debt Chart

Huadong Medicine Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.41 1.76 2.37 1.79 2.65

Huadong Medicine Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.79 1.60 1.96 2.02 2.65

Competitive Comparison of Huadong Medicine Co's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Huadong Medicine Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Huadong Medicine Co's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Huadong Medicine Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Huadong Medicine Co's Cash-to-Debt falls into.



Huadong Medicine Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Huadong Medicine Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Huadong Medicine Co's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Huadong Medicine Co  (SZSE:000963) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Huadong Medicine Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Huadong Medicine Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Huadong Medicine Co (SZSE:000963) Business Description

Traded in Other Exchanges
N/A
Address
468 Yan’an Road, Floor 7, 9 and 10, Gate No. 1, Building No. 1, Hangzhou, CHN, 310006
Huadong Medicine Co Ltd is engaged in the production and sales of antibiotics, proprietary Chinese medicine, chemical synthetic medicine and genetic engineering drugs products. It is also engaged in the wholesale, retail and distribution business of Chinese and western medicine, Chinese herbal medicine, medical apparatus, and instruments. The main business of the company is divided into pharmaceutical business sales and the industry of pharmaceutical. The product portfolio of the company includes Corbrin capsule, Cymusi, New Cyspin, Kasiping, Panlisu, Acarbose, and others.

Huadong Medicine Co (SZSE:000963) Headlines

No Headlines